Cardiology
COVID-19 cardiovascular
CV manifestations and sequelae of COVID-19
Emerging pathwayAlso known as: COVID heart, coronavirus cardiovascular, long COVID cardiac
316
Clinical questions
156
Evidence-backed
100
Claims analyzed
Cardiology
CV manifestations and sequelae of COVID-19
Synthesized from 156 evidence-backed clinical questions linked to this topic — 8 supporting the intervention, 9 against the intervention, 2 still contested.
Does mrna-1273.815 vs placebo improve outcomes in COVID-19 Virus Disease?
Moderate Certainty+ Favors benefitmrna-1273.815 vs placebo
7 studies (4,000,000 patients, 1 RCTs) provide moderate-certainty evidence for benefit of mrna-1273.815 for the outcome in COVID-19 Virus Disease.
Does nirmatrelvir vs ritonavir improve outcomes in COVID-19 Virus Disease?
Moderate Certainty≈ Likely no clinically meaningful effectnirmatrelvir vs ritonavir
4 studies (5,440 patients, 1 RCTs) provide moderate-certainty evidence showing no clinically meaningful effect of nirmatrelvir for the outcome in COVID-19 Virus Disease.
Does angiotensin-converting-enzyme inhibitors vs placebo improve outcomes in COVID-19 Virus Disease?
Low Certainty+ Favors benefitangiotensin-converting-enzyme inhibitors vs placebo
3 studies (997,217 patients) provide low-certainty evidence for benefit of angiotensin-converting-enzyme inhibitors for the outcome in COVID-19 Virus Disease.
Does covid-19 mrna vaccine vs placebo improve outcomes in COVID-19 Virus Disease?
Low Certainty− Favors harmcovid-19 mrna vaccine vs placebo
5 studies (730,625 patients) provide low-certainty evidence against benefit of covid-19 mrna vaccine for the outcome in COVID-19 Virus Disease.
Does sars-cov-2 (covid-19) vaccine, mrna-bnt162b2 omicron (kp.2) vs placebo improve outcomes in COVID-19 Virus Disease?
Low Certainty− Favors harmsars-cov-2 (covid-19) vaccine, mrna-bnt162b2 omicron (kp.2) vs placebo
9 studies (130,071 patients) provide low-certainty evidence against benefit of sars-cov-2 (covid-19) vaccine, mrna-bnt162b2 omicron (kp.2) for the outcome in COVID-19 Virus Disease.
Does ace inhibitors vs angiotensin receptor blockers improve outcomes in COVID-19 Virus Disease?
Low Certainty+ Favors benefitace inhibitors vs angiotensin receptor blockers
5 studies (76,138 patients) provide low-certainty evidence for benefit of ace inhibitors for the outcome in COVID-19 Virus Disease.
Does mrna-1273 vs placebo improve outcomes in SARS-CoV-2?
Insufficient~ Mixed resultsmrna-1273 vs placebo
2 studies (80 patients) provide insufficient evidence with mixed findings regarding mrna-1273 for the outcome in SARS-CoV-2.
Does angiotensin receptor blockers vs placebo improve outcomes in COVID-19 Virus Disease?
Insufficient~ Mixed resultsangiotensin receptor blockers vs placebo
2 studies (358 patients) provide insufficient evidence with mixed findings regarding angiotensin receptor blockers for the outcome in COVID-19 Virus Disease.
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement
European Heart Journal — Peretto G — Apr 2020
Different Types of Myocardial Injury due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant
International Heart Journal — Moriwaki K — Jan 2023
Cardiac Troponin-I, A Biomarker for Predicting COVID-Induced Myocardial Damage Prognosis
Journal of College of Physicians And Surgeons Pakistan — Rehman A — May 2023
Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study
Diabetes & Metabolism Journal — Bae J — Feb 2021
Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
COVID-19 cardiovascular (also known as COVID heart, coronavirus cardiovascular, long COVID cardiac). CV manifestations and sequelae of COVID-19
Synapse tracks 1 specific clinical question in COVID-19 cardiovascular, synthesizing the evidence for it independently: "Does hydroxychloroquine vs azithromycin improve QT Prolongation in COVID-19 Virus Disease?".
As of 2026-08-15, the scientific consensus on COVID-19 cardiovascular is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/covid-19-cardiovascular.
Deterministic synthesis from Synapse's enriched corpus — 84 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every COVID-19 cardiovascular paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search COVID-19 cardiovascular papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Journal of Korean Medical Science — Park H — Jan 2021